Reference:ICH ICH E8 Guideline R1 (2021) 5.1 - Revision history

Gxplex admin: 1 revision imported

2026-07-16T11:49:54Z

1 revision imported

← Older revision	Revision as of 13:49, 16 July 2026
(No difference)

GxPlexBot: Migrate to Template:ReferenceData for PageForms (GxPlexBot)

2026-07-16T10:55:44Z

Migrate to Template:ReferenceData for PageForms (GxPlexBot)

← Older revision		Revision as of 12:55, 16 July 2026
Line 1:		Line 1:
	{{~~#set:~~		{{ReferenceData
	\|~~HasDocument~~=Document:ICH ICH E8 Guideline R1 (2021)		\|has_document=Document:ICH ICH E8 Guideline R1 (2021)
	\|~~RefScope~~=G		\|module=3
	\|~~RefDocPart~~=5.1		\|unit=3.2.2
	\|~~RefLanguage~~=EN		\|scope=G
	\|~~RefTags~~=TAG-00077-Inc-gsk ++ TAG-00078-Exc-ssk ++ TAG-00317-Obj-set ++ TAG-00083-Enr-enr ++ TAG-00244-Def-ini		\|doc_part=5.1
	\|~~RefModule=3~~		\|language=EN
	~~\|RefUnit=3.2.2~~		\|entry_by=Florian Adragna
	}}		\|contributors=
			\|tags=TAG-00077-Inc-gsk ++ TAG-00078-Exc-ssk ++ TAG-00317-Obj-set ++ TAG-00083-Enr-enr ++ TAG-00244-Def-ini
	~~{{:Document:ICH ICH E8 Guideline R1 (2021)}}~~		\|tags_display=[[Glossary:TAG-00077-Inc-gsk\|Inclusion criteria]], [[Glossary:TAG-00078-Exc-ssk\|Exclusion criteria]], [[Glossary:TAG-00317-Obj-set\|Objective]], [[Glossary:TAG-00083-Enr-enr\|Enrolment]], [[Glossary:TAG-00244-Def-ini\|Definition]]
			\|comment=Study population selection criteria and objectives
	~~{\| class="wikitable gplx-infobox"~~		\|content=Study Population
	\|-
	~~! colspan="2" class~~=~~"gplx-infobox-header" \| Reference Details~~
	\|-
	~~! Module~~
	~~\| Module 3 — Unit 3.2.2~~
	\|-
	~~! Scope~~
	~~\| G~~
	\|-
	~~! Document part~~
	~~\| 5.1~~
	\|-
	~~! Language~~
	~~\| EN~~
	\|-
	~~! Original entry by~~
	~~\| Florian Adragna~~
	\|-
	~~! Contributors~~
	\|
	\|-
	~~! Tags~~
	\| [[Glossary:TAG-00077-Inc-gsk\|Inclusion criteria]], [[Glossary:TAG-00078-Exc-ssk\|Exclusion criteria]], [[Glossary:TAG-00317-Obj-set\|Objective]], [[Glossary:TAG-00083-Enr-enr\|Enrolment]], [[Glossary:TAG-00244-Def-ini\|Definition]]
	\|-
	~~! Comment~~
	\| Study population selection criteria and objectives
	\|}

	=~~= Content ==~~
	Study Population
	The population to be studied should be chosen to support the study objectives and is defined through the inclusion and exclusion criteria for the study		The population to be studied should be chosen to support the study objectives and is defined through the inclusion and exclusion criteria for the study
	The degree to which a study succeeds in enrolling the desired population will impact the ability of the study to meet its objectives.		The degree to which a study succeeds in enrolling the desired population will impact the ability of the study to meet its objectives.
	The study population may be narrowly defined to reduce the risk to study participants or to maximise the sensitivity of the study for detecting a certain effect. Conversely, it may be broadly defined to more closely represent the diverse populations for which the drug is intended. In general, studies conducted early in a development programme, when little is known about the safety of the drug, are more homogeneous in study population definitions. Studies conducted in the later phases of drug development or post-approval are often more heterogeneous in study population definitions. Such studies should involve participants who are representative of the diverse populations which will receive the intervention in clinical practice. Available knowledge about participant characteristics that may predict disease outcomes or effects of the intervention can be used to further define the study population.		The study population may be narrowly defined to reduce the risk to study participants or to maximise the sensitivity of the study for detecting a certain effect. Conversely, it may be broadly defined to more closely represent the diverse populations for which the drug is intended. In general, studies conducted early in a development programme, when little is known about the safety of the drug, are more homogeneous in study population definitions. Studies conducted in the later phases of drug development or post-approval are often more heterogeneous in study population definitions. Such studies should involve participants who are representative of the diverse populations which will receive the intervention in clinical practice. Available knowledge about participant characteristics that may predict disease outcomes or effects of the intervention can be used to further define the study population.
			}}

gxplex>GxPlexBot: Import from GxPlex Excel

2026-07-15T15:29:01Z

Import from GxPlex Excel

← Older revision	Revision as of 17:29, 15 July 2026
(No difference)

imported>GxPlexBot: Import from GxPlex Excel

2026-07-15T15:29:01Z

Import from GxPlex Excel

← Older revision		Revision as of 17:29, 15 July 2026
Line 4:		Line 4:
	\|RefDocPart=5.1		\|RefDocPart=5.1
	\|RefLanguage=EN		\|RefLanguage=EN
	\|~~RefTagsEN~~=		\|RefTags=TAG-00077-Inc-gsk ++ TAG-00078-Exc-ssk ++ TAG-00317-Obj-set ++ TAG-00083-Enr-enr ++ TAG-00244-Def-ini
	\|~~RefTagsOriginal~~=		\|RefModule=3
	\|~~RefTagsFR~~=		\|RefUnit=3.2.2
	}}		}}

Line 14:		Line 14:
	\|-		\|-
	! colspan="2" class="gplx-infobox-header" \| Reference Details		! colspan="2" class="gplx-infobox-header" \| Reference Details
			\|-
			! Module
			\| Module 3 — Unit 3.2.2
	\|-		\|-
	! Scope		! Scope
Line 30:		Line 33:
	\|		\|
	\|-		\|-
	! Tags ~~(EN)~~		! Tags
	\|		\| [[Glossary:TAG-00077-Inc-gsk\|Inclusion criteria]], [[Glossary:TAG-00078-Exc-ssk\|Exclusion criteria]], [[Glossary:TAG-00317-Obj-set\|Objective]], [[Glossary:TAG-00083-Enr-enr\|Enrolment]], [[Glossary:TAG-00244-Def-ini\|Definition]]
	\|-
	~~! Tags (original language)~~
	\|
	\|-
	~~! Tags (FR)~~
	\|
	\|-		\|-
	! Comment		! Comment

Gxplex admin: 1 revision imported

2026-06-29T13:28:52Z

1 revision imported

← Older revision	Revision as of 15:28, 29 June 2026
(No difference)

gxplex>GxPlexBot: Import from GxPlex Excel

2026-06-29T13:27:17Z

Import from GxPlex Excel

← Older revision		Revision as of 15:27, 29 June 2026
Line 11:		Line 11:
	{{:Document:ICH ICH E8 Guideline R1 (2021)}}		{{:Document:ICH ICH E8 Guideline R1 (2021)}}

	{\| class="gplx-infobox"		{\| class="wikitable gplx-infobox"
	\|-		\|-
	! colspan="2" class="gplx-infobox-header" \| Reference Details		! colspan="2" class="gplx-infobox-header" \| Reference Details

Gxplex admin: 1 revision imported

2026-06-29T13:07:59Z

1 revision imported

← Older revision	Revision as of 15:07, 29 June 2026
(No difference)

gxplex>GxPlexBot: Import from GxPlex Excel

2026-06-29T13:06:54Z

Import from GxPlex Excel

← Older revision	Revision as of 15:06, 29 June 2026
(No difference)

Gxplex admin: 1 revision imported

2026-06-29T12:51:57Z

1 revision imported

← Older revision	Revision as of 14:51, 29 June 2026
(No difference)

gxplex>GxPlexBot: Import from GxPlex Excel

2026-06-29T12:27:21Z

Import from GxPlex Excel

← Older revision		Revision as of 14:27, 29 June 2026
Line 9:		Line 9:
	}}		}}

	~~== Document Information ==~~
	{{:Document:ICH ICH E8 Guideline R1 (2021)}}		{{:Document:ICH ICH E8 Guideline R1 (2021)}}

	~~== Reference Details ==~~		{\| class="gplx-infobox"
	{\| class="~~wikitable" style="width:100%;~~"
	\|-		\|-
	! ~~scope~~="~~row~~" ~~style~~="~~width:200px;~~" \| Scope		! colspan="2" class="gplx-infobox-header" \| Reference Details
			\|-
			! Scope
	\| G		\| G
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Document part		! Document part
	\| 5.1		\| 5.1
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Language		! Language
	\| EN		\| EN
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Original entry by		! Original entry by
	\| Florian Adragna		\| Florian Adragna
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Contributors		! Contributors
	\|		\|
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Tags (EN)		! Tags (EN)
	\|		\|
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Tags (original language)		! Tags (original language)
	\|		\|
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Tags (FR)		! Tags (FR)
	\|		\|
	\|-		\|-
	! ~~scope="row" \|~~ Comment		! Comment
	\| Study population selection criteria and objectives		\| Study population selection criteria and objectives
	\|}		\|}

	== ~~Text~~ ==		== Content ==
	Study Population		Study Population
	The population to be studied should be chosen to support the study objectives and is defined through the inclusion and exclusion criteria for the study		The population to be studied should be chosen to support the study objectives and is defined through the inclusion and exclusion criteria for the study
	The degree to which a study succeeds in enrolling the desired population will impact the ability of the study to meet its objectives.		The degree to which a study succeeds in enrolling the desired population will impact the ability of the study to meet its objectives.
	The study population may be narrowly defined to reduce the risk to study participants or to maximise the sensitivity of the study for detecting a certain effect. Conversely, it may be broadly defined to more closely represent the diverse populations for which the drug is intended. In general, studies conducted early in a development programme, when little is known about the safety of the drug, are more homogeneous in study population definitions. Studies conducted in the later phases of drug development or post-approval are often more heterogeneous in study population definitions. Such studies should involve participants who are representative of the diverse populations which will receive the intervention in clinical practice. Available knowledge about participant characteristics that may predict disease outcomes or effects of the intervention can be used to further define the study population.		The study population may be narrowly defined to reduce the risk to study participants or to maximise the sensitivity of the study for detecting a certain effect. Conversely, it may be broadly defined to more closely represent the diverse populations for which the drug is intended. In general, studies conducted early in a development programme, when little is known about the safety of the drug, are more homogeneous in study population definitions. Studies conducted in the later phases of drug development or post-approval are often more heterogeneous in study population definitions. Such studies should involve participants who are representative of the diverse populations which will receive the intervention in clinical practice. Available knowledge about participant characteristics that may predict disease outcomes or effects of the intervention can be used to further define the study population.